Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: An open, 16 month, comparative study

International Journal of Clinical Practice

Volumn 58, Issue 4, 2004, Pages 346-353

  Moretti, Rita ^a   Torre, P ^a   Antonello, R M ^a   Cazzato, G ^a   Griggo, S ^a   Ukmar, M ^a   Bava, A ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Attention; Behaviour; Cholinesterase inhibition; Executive function; Rivastigmine; Vascular dementia

Indexed keywords

ACETYLCHOLINESTERASE; ACETYLSALICYLIC ACID; AMLODIPINE; BENZODIAZEPINE; CHOLINESTERASE; NEUROLEPTIC AGENT; NIMODIPINE; RIVASTIGMINE;

AGED; ANOREXIA; ARTICLE; ATTENTION; BEHAVIOR; BINDING AFFINITY; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIZZINESS; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; MUSCLE CONTRACTION; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ASPIRIN; CARBAMATES; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA, VASCULAR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NIMODIPINE; PHENYLCARBAMATES; PSYCHOTIC DISORDERS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 2642520333     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00127.x     Document Type: Article

References (44)

1. Ebly EM, Parhad IM, Hogan DB, Fung TS. Prevalence and types of dementia in the very old. Results from the Canadian Study of Health and Aging. Neurology 1994; 44: 1593-9.
2. Erkinjuntti T. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs 1999; 12: 447-51.
3. Rockwood K, Bowler J, Erkinjuntti T, Hachinski V, Wallin A. Subtypes of vascular dementia. Alzheimer Dis Assoc Disord 1999; 13: S59-S63.
4. Miech RA, Breitner JCS, Zandi PP et al. Incidence of AD may decline in the early 90s for men, later for women. Neurology 2002; 58: 209-18.
5. McPherson SE, Cummings JL. Neuropsychological aspects of vascular dementia. Brain Cogn 1996; 31: 261-82.
6. Looi JCL, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999; 53: 670-8.
7. Chui H. Dementia associated with subcortical ischemic vascular disease Philadelphia: American Academy, 2001, 2FC.005-89-107.
8. Meyer JS, Rogers RL, McClintic K et al. Randomized clinical trial of daily aspirin in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989; 37: 549-55.
9. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002; 3: CD000147.
10. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 1994; 5: 163-7.
11. Tohgi H, Abe T, Kimura M et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer type dementia. J Neural Transm 1996; 103: 1211-20.
12. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999; 12: 307-23.
13. Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolize acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002; 9: 88-93.
14. Greig NH, Utsuki T, Qian-sheng Y et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17: 1-7.
15. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64-70.
16. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract 2002; Suppl. 127: 6-19.
17. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow up. Eur J Neurol 2001; 8: 361-2.
18. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002; 203-204: 141-6.
19. Folstein M, Folstein S, McHugh P. Mini-Mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association, 1994.
21. Romàn GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60.
22. Erkinjuntti T, Ketonen L, Sulkava R, Vuorialho M, Palo J. CT in the differential diagnosis between Alzheimer's disease and vascular dementia. Acta Neurol Scand 1987; 75: 262-70.
23. Agid Y, Dubois B, on behalf of the International Rivastigmine Investigators, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res 1998; 59: 837-45.
24. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
25. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987; 48: 214-328.
26. Lezak M. Neuropsychological Assessment New York: Oxford University Press, 1995.
27. Wechsler D. Wechsler adult intelligence scale-R-Manual New York, NY: Psychological Corp, 1981.
28. Manos PJ. The utility of the ten-point clock test as a screen for cognitive impairment in general hospital patients. Gen Hosp Psychiatry 1997; 8: 469-76.
29. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Maryland State Med J 1965; 14: 61-5.
30. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-89.
31. Reisberg B, Borenstein J, Salob SP et al. Behavioural symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(S): 9-15.
32. Ryden MB. Aggressive behaviour in persons with dementia who live in the community. Alzheimer Dis Assoc Disord 1988; 2: 342-55.
33. Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psych Res 1983; 17: 37-49.
34. Conwell Y, Forbes NT, Cox C, Caine ED. Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating scale. J Am Geriatr Soc 1993; 41: 38-41.
35. Parmalee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating scale in a geriatric residential population. J Am Geriatr Soc 1995; 43: 130-7.
36. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia. Curr Ther Res 2002; 63: 443-58.
37. Wilkinson D, Doody R, Helme R et al. Donepezil in vascular dementia: a randomized, placebo-controlled study Neurology 2003; 61: 479-86.
38. Black S, Roman GC, Geldmacher DS et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-30.
39. Salloway S, Pratt RD, Perdomo CA for the Donepezil 307 and 308 Study Groups. A comparison of the cognitive benefits of donepezil in patients with cortical versus subcortical vascular dementia: a subanalysis of two 24-week, randomized, double-blind, placebo-controlled trials. Neurology 2003; 60 (Suppl. 1): A141-2.
40. Sharma T, Kumari V, Mitterschiffthaler M et al. Cognitive Effects of Rivastigmine in Alzheimer's Disease: an FMRI Study. Poster Presented at the American College of Neuropsychopharmacology 40th Annual Meeting, Waikoloa, Hawaii, 9-13 December 2001.
41. Venneri A, Shanks MF, Staff RT et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002; 13: 83-96.
42. Rombouts SARB, Barkhof F, van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 73: 665-71.
43. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comparative Neurol 1998; 393: 374-90.
44. Erkinjuntti T, Skoog I, Lane R, Andrews C. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in the Alzheimer brain. Int J Clin Pract 2003; 57: 756-60.